Octagon Capital Advisors Discloses 2.25M Share Stake in Reneo Pharma

TL;DR

**Octagon Capital Advisors just revealed a 2.25M share stake in Reneo Pharma.**

AI Summary

Octagon Capital Advisors LP, a Delaware-based investment firm, reported on February 5, 2024, that it beneficially owns 2,250,000 shares of Reneo Pharmaceuticals, Inc. common stock, representing shared voting and dispositive power. This filing, triggered by an event on December 31, 2023, indicates a significant institutional stake in Reneo, suggesting a vote of confidence from Octagon Capital Advisors LP. This matters to investors as large institutional holdings can signal stability and potential future interest in the stock.

Why It Matters

This filing reveals a major institutional investor, Octagon Capital Advisors LP, holds a substantial stake in Reneo Pharmaceuticals, which can influence stock stability and investor perception.

Risk Assessment

Risk Level: low — An institutional investor taking a significant stake is generally seen as a positive signal, reducing perceived risk.

Analyst Insight

A smart investor would note this institutional vote of confidence and consider further research into Reneo Pharmaceuticals' fundamentals and pipeline, as large institutional ownership can sometimes precede positive price movements.

Key Numbers

• 2,250,000 — Shares Beneficially Owned (Represents the total number of Reneo Pharmaceuticals shares Octagon Capital Advisors LP has shared voting and dispositive power over.)
• 12/31/2023 — Date of Event (The date that triggered the requirement for this SC 13G filing.)
• 75974E103 — CUSIP Number (Unique identification number for Reneo Pharmaceuticals' Common Stock.)

Key Players & Entities

• Octagon Capital Advisors LP (company) — reporting person and investment firm
• Reneo Pharmaceuticals, Inc. (company) — subject company, issuer of the securities
• OCTAGON INVESTMENTS MASTER FUND LP (company) — group member
• TING JIA (person) — group member
• 03 Life Sciences (company) — organization name associated with Reneo Pharmaceuticals

Forward-Looking Statements

• Reneo Pharmaceuticals' stock may experience increased investor confidence due to this significant institutional holding. (Reneo Pharmaceuticals, Inc.) — medium confidence, target: Q1 2024
• Octagon Capital Advisors LP may increase its stake in Reneo Pharmaceuticals if the company's pipeline progresses positively. (Octagon Capital Advisors LP) — low confidence, target: Q3 2024

FAQ

Key Financial Figures

• $0.0001 — INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securiti

Filing Documents

• j15240sc13g.htm (SC 13G) — 64KB
• 0001214659-24-001920.txt ( ) — 65KB

(a)

Item 1(a). Name of Issuer: RENEO PHARMACEUTICALS, INC.

(b)

Item 1(b). Address of Issuer’s Principal Executive Offices: 18575 Jamboree Road, Suite 275-S Irvine, CA 92612

(a)

Item 2(a). Name of Person Filing: This statement is being jointly filed by: • Octagon Capital Advisors LP, a Delaware limited partnership, (“Octagon”) • Octagon Investments Master Fund LP, an exempted limited partnership established in the Cayman Islands ("Master Fund") • Ting Jia, as the principal beneficial owner of Octagon (“Mr. Jia”). Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Octagon serves as the investment manager of the Master Fund. Mr. Jia is the managing member of Octagon. By virtue of these relationships, each of Octagon and Mr. Jia may be deemed to beneficially own the Issuer’s Common Shares directly owned by the Master Fund.

(b)

Item 2(b). Address of Principal Business Office or, if none, Residence: 645 Madison Avenue 21 st Floor, New York, NY 10065

(c)

Item 2(c). Citizenship: USA

(d)

Item 2(d). Title of Class of Securities: Common Stock, $0.0001 Par Value (“Common Shares” or “Shares”)

(e)

Item 2(e). CUSIP Number: 75974E103 Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) ¨ Broker or dealer registered under Section 15 of the Act; (b) ¨ Bank as defined in Section 3(a)(6) of the Act; (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act; (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940; (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; (j) ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); (k) ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 2,250,000; (b) Percent of Class: The percentage reported on this Schedule 13G, 6.75%, based on 33,311,787 shares of common stock outstanding as of November 9, 2023, as reported in the Form 10-Q filed by the issuer on November 13, 2023. 6.75% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: (ii) shared power to vote or to direct the vote: 2,250,000 (iii) sole power to dispose or to direct the disposition of: (iv) shared power to dispose

View Full Filing

View this SC 13G filing on SEC EDGAR